Bedaquiline: A novel antitubercular agent for the treatment of multidrug-resistant tuberculosis

Pharmacotherapy

Volumn 34, Issue 11, 2014, Pages 1187-1197

  Worley, Marylee V ^a   Estrada, Sandy J ^a  

^a Lee Memorial Health System   (United States)

Author keywords

ATP synthase; bedaquiline; diarylquinoline; MDR TB; multidrug resistant tuberculosis; R207910; TMC207; tuberculosis

Indexed keywords

BEDAQUILINE; KETOCONAZOLE; MOXIFLOXACIN; PLACEBO; ATP SYNTHASE SUBUNIT C, MYCOBACTERIUM TUBERCULOSIS; BACTERIAL PROTEIN; ENZYME INHIBITOR; NEW DRUG; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANOREXIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTRANSAMINASEMIA; IN VITRO STUDY; LOADING DRUG DOSE; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; OUTCOME ASSESSMENT; QT PROLONGATION; RASH; SINGLE DRUG DOSE; THORAX PAIN; TREATMENT DURATION; TREATMENT FAILURE; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG INTERACTION; ENZYMOLOGY; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANIMALS; ANTITUBERCULAR AGENTS; ATP SYNTHETASE COMPLEXES; BACTERIAL PROTEINS; DIARYLQUINOLINES; DRUG INTERACTIONS; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; MYCOBACTERIUM TUBERCULOSIS; PRACTICE GUIDELINES AS TOPIC; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84908877912     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1482     Document Type: Article

References (30)

1. World Health Organization. Global tuberculosis report 2013. Available from http://www.who.int/tb/publications/global-report/en/index.html. Accessed December, 31 2013.
2. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta: CDC; 2013. Available from http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed March 15, 2014.
3. Centers for Disease Control and Prevention. Provisional CDC Guidelines for the Use and Safety Monitoring of Bedaquiline Fumarate (Sirturo) for the Treatment of Multidrug-Resistant Tuberculosis. MMWR 2013; 62 (No. 9 RR 1-11).
4. World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis Interim policy guidance. Available from http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482-eng.pdf?ua=1. Accessed March 15, 2014.
5. Matteelli A, Carvahlo AC, Dooley KE, Kritski A,. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010; 5: 849-58.
6. Sirturo (bedaquiline) [Package insert]. Titusville, NJ: Janssen Therapeutics; 2012.
7. Haagsma AC, Podasca I, Koul A, et al. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS ONE 2011; 6: e23575.
8. Mesens N, Margino S, Hansen E, et al. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol In Vitro 2010; 24: 1417-25.
9. ACPS meeting. United States Federal Drug Administration; Apr 14, 2010. The regulatory challenges of drug-induced phospholipidosis. Available from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/advisorycomadvisorycommitteeforpharmaceuticalscienceandclinicalp/ucm210798.pdf. Accessed May 26, 2014.
10. Rouan MC, Lounis N, Gevers T, et al. Pharmacokinetics and pharmacodynamics of TMC207 and Its N-Desmethyl metabolite in a murine model of tuberculosis. Antimicrob Agents Chemother 2012; 56: 1444-51.
11. Shayman JA, Abe A,. (2013). Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta 1831: 602-11.
12. Koul A, Vrankx L, Dendouga N, Balemans W, Van den Wyngaert I, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-80.
13. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223-7.
14. Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W,. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob Agents Chemother 2006; 50: 2853-6.
15. Lerat I, Cambau E, Roth dit Bettoni R, et al. In vivo evaluation of antibiotic activity against Mycobacterium abscessus. J Infect Dis 2014; 209: 905-12.
16. Huitric E, Verhasselt P, Andries K, Hoffner E,. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2007; 51: 4202-4.
17. Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI,. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010; 54: 1022-8.
18. Diacon A, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-405.
19. Adams K, Takaki K, Connolly LE, et al. Drug tolerance in replicating mycobacteria mediated by macrophage-induced efflux mechanism. Cell 2011 Apr 1; 145: 39-53.
20. Gupta S, Cohen K, Winglee K, Maiga M, Diarra B, Bishai W,. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 574-6.
21. Hartkoorn R, Upekar A, Cole S,. Cross-resistance between clofazimine and bedaquiline through up-regulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 2979-81.
22. Rustomjee R, Diacon AH, Allen J,. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-5.
23. Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedauiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 2012; 56: 3271-6.
24. Food and Drug Administration. Briefing package: TMC207 (bedaquiline). Treatment of patients with MDR-TB. Anti-Infective Drugs Advisory Committee Meeting Silver Spring, MD; November 28, 2012. Available from http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/anti-infectivedrugsadvisorycommittee/ucm329260.pdf Accessed March 14, 2014.
25. Lenaerts AJ, Hoff D, Aly S, et al. Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by R207910. Antimicrob Agents Chemother 2007; 51: 3338-45.
26. Shang S, Shanley CA, Caraway ML, et al. Activities of TMC207, rifampin and pyrazinamide against Mycobacterium tuberculosis infection in Guinea pigs. Antimicrob Agents Chemother 2011; 55: 124-31.
27. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013; 57: 2199-203.
28. Morganroth J, Dimarco JP, Anzueto A, Niederman MS, Choudhri S,. A randomized trial comparing the cardiac rhythm safety of moxifloxacin vs. levofloxacin in elderly patients hospitalized with community acquired pneumonia. Chest 2005; 128: 3398-406.
29. Dooley KE, Park JG, Swindells S, et al. Safety, tolerability and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Study A5267. J Acquir Immune Defic Syndr 2012; 59: 455-62.
30. Svensson EM, Aweeka F, Park J, marzan F, Dooley KE, Karlsson MO,. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013; 57: 2780-7.